'Peptides are legal again' — what the reclassification actually means

The formal regulatory action came in two parts.

On April 15, 2026, the FDA announced that 12 peptides would be removed from Category 2 of its 503A bulk drug substances categories after seven calendar days. The stated reason: the underlying nominations for inclusion on the bulks list — the applications that had originally put them in Category 2 review — had been withdrawn.

On April 16, 2026, the FDA published a Federal Register notice (Docket No. FDA-2025-N-6895) announcing a PCAC public meeting to evaluate seven of those peptides for potential inclusion on the 503A Bulks List.

The removal became effective approximately April 22, 2026.

Before this, these peptides sat in Category 2 — a designation meaning the FDA had identified significant safety concerns and that they were ineligible for the agency's interim enforcement discretion policy. Being removed from Category 2 means those safety-risk designations have been lifted. It does not mean the substances have been approved, or that compounding them is currently authorized.

Law firm Polsinelli, writing on April 22, 2026, put it this way: That procedural removal should not be read as a go-ahead to compound these peptides. Under FDA's current policy, removal of a bulk drug substance from Category 2 does not, on its own, authorize use of that substance in compounding or bring it within FDA's interim enforcement discretion policy for substances in Category 1.

FDA's 503A categories are an interim framework for classifying bulk drug substances that have been nominated for the 503A Bulks List while the agency evaluates them.

Category 1 is for substances where FDA has received sufficient supporting information and for which the agency generally applies interim enforcement discretion — meaning pharmacies are unlikely to be penalized for compounding those substances while formal evaluation proceeds.

Category 2 is for substances where FDA has identified significant safety concerns. These are ineligible for the Category 1 enforcement-discretion policy.

Being in Category 1 does not mean a substance is FDA-approved. It means a licensed 503A compounding pharmacy may use it in a compound for an individual patient under a valid prescription while the formal 503A Bulks List review proceeds.

The important point: these 12 peptides are not currently in Category 1. They were removed from Category 2. Where they go next — whether they are added to the 503A Bulks List after a PCAC review — is exactly what the advisory committee process is designed to answer.

The FDA scheduled two separate PCAC meetings.

July 23-24, 2026 (7 peptides reviewed):

• July 23: BPC-157, KPV, TB-500, MOTS-c
• July 24: Emideltide (DSIP), Semax, Epitalon

Before February 2027 (5 additional peptides):

• GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF

These 12 are the total scope of the April 2026 action. Earlier social media posts — some tracing back to informal statements made on a podcast in February 2026 — referenced a larger and sometimes inconsistent count of substances. The formal Federal Register notice (FDA-2025-N-6895) is the authoritative document.

The PCAC is an advisory body. It reviews safety and clinical need data, hears public comment, and issues recommendations to the FDA. It can recommend a substance for inclusion on the 503A Bulks List, recommend against inclusion, or recommend inclusion with conditions.

The FDA is not bound by advisory committee recommendations, but it weighs them. After the committee meets, any formal addition to the 503A Bulks List would require additional notice-and-comment rulemaking — a separate step with its own timeline.

The public comment period for the July 23-24 PCAC meeting is open until July 22, 2026. Anyone can submit a comment to Docket No. FDA-2025-N-6895 at regulations.gov.

Even if the committee votes favorably on any of these peptides, that does not immediately change what licensed pharmacies can compound. The gap between a favorable PCAC recommendation and operational availability at a compounding pharmacy will be measured in months, not days.

• Whether any of the 12 peptides will receive a favorable PCAC recommendation
• What safety data the committee will weigh, and whether any will raise unresolved concerns
• How long formal rulemaking would take after a favorable recommendation
• What quality, sterility, and dosing standards licensed compounders would be required to meet
• Whether the 5 peptides scheduled for pre-February 2027 review will receive their meeting on schedule

These peptides are not FDA-approved for any indication. They have not been added to any FDA-authorized list. The FDA has not issued any statement saying patients may now obtain or use them.

Online sources describing these substances as now legal or available through compounding are inaccurate. The regulatory pathway that could eventually authorize their compounding has advanced by one procedural step. That is meaningful to pharmacists and regulators tracking the process. It does not change what a patient can currently obtain from a licensed source.

If you have been obtaining any of these peptides from unregulated online sources labeled as research chemicals, that legal situation has not changed. Those products are not intended for human use, they are not manufactured to pharmaceutical-grade standards, and no FDA action in April 2026 authorized their use.

• If I have been using a peptide that is under FDA review, how does that affect my current treatment plan?
• If one of these peptides eventually becomes available through licensed compounding, what evidence would you want to see before considering it?
• What distinguishes a licensed 503A compounding pharmacy from a vendor selling research chemicals?

The FDA advisory committee calendar page lists background documents and meeting logistics. Background documents are typically published approximately two weeks before the meeting date.

After the meeting, FDA publishes transcripts and committee votes. Those documents — not vendor blogs, social media summaries, or podcast clips — are the primary source for understanding what the committee actually found.

The public comment docket is open at regulations.gov until July 22, 2026 — search for Docket No. FDA-2025-N-6895.

If you are wondering whether any of the reclassified peptides are now available by prescription, ask a licensed prescriber — not a vendor website. Operational availability depends on a multi-step process that is still in progress.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Federal Register Notice 2026-07361. FDA Docket FDA-2025-N-6895. April 16, 2026. govinfo.gov
• FDA Advisory Committee Calendar: PCAC Meeting July 23-24, 2026. fda.gov
• Polsinelli. Tiny Chains, Big Changes? What FDA's Latest Actions Mean for Peptide Compounding. April 22, 2026. polsinelli.com
• Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings. orrick.com
• Pharmacy Times. Chammout R, PharmD. The Peptide Reclassification Everyone's Talking About. pharmacytimes.com
• FDA Law Blog. FDA's Pep(tide) Rally! April 21, 2026. thefdalawblog.com